CHMP Backs Expanded ENFLONSIA Indication – Merck’s RSV Antibody Recommended for High‑Risk Children Through Their Second Season

Fineline Cube
4 Min Read
Summarize with AI

Merck & Co., Inc. (MSD) (NYSE: MRK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of an expanded indication for ENFLONSIA (clesrovimab) to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children up to 24 months of age at increased risk for severe RSV disease through their second RSV season. The recommendation would broaden the reach of Merck’s extended half‑life monoclonal antibody beyond first‑season newborns and infants, aligning the EU label with a pending U.S. expansion.

- Advertisement -

Regulatory Milestone

ItemDetail
AgencyCHMP / EMA (European Union)
Opinion TypePositive opinion recommending expanded indication
ProductENFLONSIA (clesrovimab), extended half‑life monoclonal antibody
Proposed IndicationPrevention of RSV LRTD in children up to 24 months at increased risk for severe RSV disease through their second RSV season
Existing ApprovalFDA‑approved for passive immunization to prevent RSV LRTD in newborns and infants born during or entering their first RSV season
Announcement Date14 November 2026
Next StepsEuropean Commission decision on the label expansion; parallel FDA sBLA accepted with PDUFA date of 22 March 2027

Drug Profile & Mechanism of Action

  • Molecule: Clesrovimab (ENFLONSIA) – Merck’s extended half‑life monoclonal antibody (mAb) providing passive immunization against RSV.
  • Target Disease: RSV lower respiratory tract disease (LRTD), the leading infectious cause of infant hospitalization worldwide, with high‑risk children remaining vulnerable through their second RSV season.
  • Differentiator: Extended half‑life design enables single‑dose seasonal protection, and the proposed expansion extends coverage to children up to 24 months at increased risk for severe disease.
  • Current Label: Approved in the U.S. for newborns and infants born during or entering their first RSV season.

Clinical Evidence – Phase 3 SMART Trial

ElementDetail
TrialSMART (MK‑1654‑007; NCT04938830)
PhasePhase 3
RoleSupports the CHMP positive opinion
ResultsPositive, as reported; specific endpoint data not disclosed in this announcement

The CHMP opinion is supported by positive results from the Phase 3 SMART trial (MK‑1654‑007) (NCT04938830). As previously announced, the FDA accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA covering the same high‑risk population under two years of age through the second RSV season, with a PDUFA action date of 22 March 2027 – setting up near‑term synchronized label expansions in both the U.S. and EU.

Market Impact & Outlook

  • Addressable Population Expansion: Extending coverage through the second RSV season for high‑risk children materially enlarges the eligible population beyond first‑season infants, strengthening ENFLONSIA’s commercial runway in the fast‑growing RSV prevention market.
  • Dual‑Market Momentum: With the CHMP opinion in hand and a March 2027 PDUFA date in the U.S., Merck is positioned for coordinated transatlantic label expansion of its flagship RSV antibody.
  • Competitive Landscape: The RSV immunization market is intensifying; a second‑season indication would differentiate ENFLONSIA among monoclonal antibody competitors focused primarily on first‑season protection.
  • Public Health Positioning: High‑risk children – including those with prematurity or underlying cardiopulmonary conditions – face elevated severe RSV burden; broader prophylaxis coverage supports reduced hospitalizations across two consecutive seasons.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the regulatory review of ENFLONSIA, the anticipated European Commission decision following the CHMP opinion, the FDA sBLA review and PDUFA timeline, and commercial expectations. Actual results may differ due to risks including final regulatory determinations, clinical outcomes, market adoption, reimbursement decisions, and competitive dynamics.-Fineline Info & Tech

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *